MedTrace Logo

The Effect of PAS on the Pharmacokinetics of Tenofovir in Healthy Subjects

NCT03070405 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-03-03

No results posted yet for this study

Summary

The main purpose of this study is to evaluate whether PAS will change the PK parameters of tenofovir.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Tenofovir disoproxil fumarate 300mg

Single oral dose on the first day of each period

DRUG

Para-aminosalicylic acid Ca granule 5.28 g

Twice daily oral administration from the first day of each period to the seventh dose

Sponsors & Collaborators

  • Inje University

    lead OTHER

Principal Investigators

  • Jae-Gook Shin, MD, PhD · Inje University

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2017-03-31
Completion
2017-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03070405 on ClinicalTrials.gov